Company Overview of CureVac GmbH
CureVac GmbH, a biopharmaceutical company, develops therapeutic messenger RNA vaccines for cancer and prophylactic vaccines for infectious diseases. The company provides RNActive molecules as immunotherapeutics for the treatment of cancer and as prophylactic vaccines against infectious diseases. It also develops adjuvants based on non-coding RNAs (RNAdjuvant) for enhancing the immune response of other vaccines. CureVac GmbH has strategic partnership with Janssen Pharmaceuticals, Inc. and Sanofi Pasteur S.A. The company was founded in 2000 and is based in Tubingen, Germany.
Founded in 2000
49 70 71 9 20 53 100
49 70 71 9 20 53 101
Key Executives for CureVac GmbH
CureVac GmbH Key Developments
Similar Private Companies By Industry
|Lichtwer Pharma AG||Europe|
|Alsitan GmbH & Co. KG||Europe|
|IDT Biologika GmbH||Europe|
|InterMed Discovery GmbH||Europe|
|Salutas Pharma GmbH||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact CureVac GmbH, please visit www.curevac.com. Company data is provided by Capital IQ. Please use this form to report any data issues.